CollagenX is a potential addition to every case type currently addressed by Xtant's biologics portfolio, as well as procedures performed in other surgical disciplines. Sean Browne, President and CEO of Xtant Medical, stated, "The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, ...